STOCKHOLM, May 7, 2020 /PRNewswire/ -- "The number of
patients treated with Buvidal® increased by 90 percent in the
quarter"
Summary first quarter
2020
- Total revenues of SEK 49.3
million (18.5), an increase of
167%
- Product sales were SEK 48.6
million (11.0), an increase of
343%
- Product sales increased by 60% compared to previous
quarter
- The estimated number of patients in treatment with Buvidal®
increased by 90% to 7,500 in EU and Australia
- A market authorization application for Buvidal was submitted to
the Swiss Agency for Therapeutic
Products
- The Australian Therapeutic Goods Administration extended
prescribing of Buvidal to include general practitioners after a
6-month trial period among opioid dependence
specialists
- Clinical trial application granted for long-acting
treprostinil, CAM2043, for the treatment of patients with Raynaud's
phenomenon
- Two new research collaborations with international
pharmaceutical companies initiated, applying FluidCrystal
technologies in new therapeutic areas
Significant event after the
period
- Camurus announces strong first quarter demand for Buvidal and
reiterates the financial outlook for 2020 with expected revenues in
the higher interval
Outlook for
2020
- Net revenues are expected to be in the region of SEK 290-330 million*, with product sales of
SEK 240-280 million. Operating
expenses are expected to be in the region of SEK 570-610 million.
* excluding milestone payments relating to Brixadi™ in the
US
Financial summary first quarter
2020
- Total Revenue MSEK 49.3 (18.5) whereof product sales MSEK
48.6
(11.0)
- OPEX MSEK 117.3
(99.4)
- Operating result MSEK -76.9
(-84.4)
- Result for the period MSEK -61.6
(-67.6)
- Earnings per share SEK -1.19
(-1.62), before and after
dilution
- Cash position MSEK 291.3 (406.6)
Fredrik Tiberg, President and
CEO:
"Camurus started 2020 with strong growth in revenue driven by
increasing demand for weekly and monthly Buvidal. We saw a 90
percent increase in the number of patients receiving treatment in
the quarter. Buvidal is now the market leader in both Finland and Norway, with the strongest growth occurring in
Australia. This positive trend in
all markets was partly catalyzed by the ongoing Covid-19 pandemic,
as treatment providers recognized the benefits Buvidal offers in
terms of reducing the treatment burden for both patients and
healthcare professionals in a hard-pressed healthcare sector.
During this quarter, we continued to improve the availability of
Buvidal in our markets. The Australian regulatory agency extended
access, allowing GPs - who treat the majority of patients with
opioid dependence - to prescribe Buvidal. In Germany and Austria, renumeration and legislative changes
were put forward to facilitate access to long-acting
medications."
Audiocast
Financial analysts and media are invited to attend a telephone
conference and presentation of the first quarter results today at
2 pm (CET). The conference call can
also be followed by a link on camurus.com or via external link:
https://financialhearings.com/event/12772
About Camurus
Camurus is a Swedish, science-led biopharmaceutical company
committed to developing and commercializing innovative, long-acting
medicines for the treatment of severe and chronic conditions. New
drug products with best-in-class potential are conceived based on
the company's proprietary FluidCrystal® drug delivery technologies
and its extensive R&D expertise. Camurus' clinical pipeline
includes products for the treatment of cancer, endocrine diseases,
pain and addiction, which are developed in-house and in
collaboration with international pharmaceutical companies. The
company's shares are listed on Nasdaq Stockholm under the ticker
CAMX. For more information, visit www.camurus.com.
This information is information that Camurus AB is obliged to
make public pursuant to the EU Market Abuse Regulation and the
Swedish Securities Markets Act. The information was submitted for
publication, through the agency of the chief executive officer,
1.00 PM CET on 7 May 2020.
For more information:
Fredrik Tiberg, CEO and Head of
Research
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/camurus-ab/r/camurus--interim-report-january-march-2020,c3106209
The following files are available for download:
|
https://mb.cision.com/Main/13456/3106209/1243645.pdf
|
Camurus Interim
Report Q1 2020.pdf
|